Stella Diagnostics Inc.
Stella Diagnostics Inc. (SLDX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
sldx · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Medical - Diagnostics & Research · 5 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Stella Diagnostics Inc.You SLDX | $2M | N/A | — | -$0.01 |
 Cann Group Limited CNGGF | $1M | N/A | — | -$0.04 |
 Dogecoin Cash, Inc. DOGP | $2M | N/A | — | -$0.00 |
 Interpace Biosciences, Inc. IDXG | $47M | 0.22x | — | $5.55 |
 IR-Med Inc. IRME | $1M | N/A | — | -$0.03 |
 Revive Therapeutics Ltd. RVVTF | $11M | N/A | — | -$0.03 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Stella Diagnostics Inc. (SLDX) measures how much investors pay for each dollar of the company's trailing earnings. SLDX's current PE ratio of N/A is calculated by dividing its stock price of $0.02 by its TTM earnings per share of -$0.01.
Frequently asked questions
SLDX pe ratio · 6 questionsSLDX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.02 and TTM EPS of -$0.01. Data sourced from Financial Modeling Prep via SLDX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Stella Diagnostics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09